BERLIN, Aug 5 (Reuters) - Losses at Germany's BioNTech

quadrupled year-on-year in the second quarter, the

company said on Monday, as it banks on a strategy shift towards

new cancer treatments following a sharp drop-off in sales of its

COVID-19 vaccine.

BioNTech reported a second-quarter net loss of 807.8 million

euros ($885.03 million), versus a loss of 190.4 million a year

earlier.

BioNTech confirmed its 2024 guidance for revenue in a range

of 2.5 billion euros to 3.1 billion euros, most of which is

expected to accrue at the end of the year.

($1 = 0.9127 euros)

(Writing by Rachel More, Editing by Miranda Murray)